CD4 Count and Tuberculosis Risk in HIV-positive Adults Not on ART: a Systematic Review and Meta-analysis

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2017 Dec 21

PMID 29259846

Citations 26

Authors

Penelope K Ellis

Willam J Martin

Peter J Dodd

Affiliations

Soon will be listed here.

Abstract

Background: CD4 cell count in adults with human immunodeficiency virus (HIV) infection (PLHIV) not receiving antiretroviral therapy (ART) influences tuberculosis (TB) risk. Despite widespread use in models informing resource allocation, this relationship has not been systematically reviewed.

Methods: We systematically searched MEDLINE, Aidsinfo, Cochrane review database and Google Scholar for reports in English describing TB incidence stratified by updated CD4 cell count in cohorts of HIV-positive adults (age ≥15 years) not on ART (PROSPERO protocol no: CRD42016048888). Among inclusion criteria were: reporting precision for TB incidence, repeated CD4 measurements, and TB incidence reported for those not on ART or monotherapy. Study quality was assessed via the Newcastle-Ottawa tool for cohort studies. A Bayesian hierarchical model was fitted to estimate the pooled factor increase in TB incidence with respect to CD4 cell count decrement.

Results: A total of 1,555 distinct records were identified from which 164 full text articles were obtained. Common reasons for exclusion of full texts were: no valid TB incidence, no repeat CD4 measurements, and not reporting TB incidence by ART status. The seven studies included reported on 1,206 TB cases among 41,271 individuals, with a typical median follow-up of four years. Studies were generally rated as moderate or high quality. Our meta-analysis estimated a 1.43 (95% credible interval: 1.16-1.88)-fold increase in TB incidence per 100 cells per mm decrease in CD4 cell count.

Discussion: Our analysis confirms previous estimates of exponential increase in TB incidence with declining CD4 cell count in adults, emphasizing the importance of early ART initiation to reduce TB risk in PLHIV.

Citing Articles

Immune correlates of early clearance of Mycobacterium tuberculosis among tuberculosis household contacts in Indonesia.

Setiabudiawan T, Apriani L, Verrall A, Utami F, Schneider M, Indrati A Nat Commun. 2025; 16(1):309.

PMID: 39747050 PMC: 11695729. DOI: 10.1038/s41467-024-55501-6.

Investigating the Determinants of Mortality before CD4 Count Recovery in a Cohort of Patients Initiated on Antiretroviral Therapy in South Africa Using a Fine and Gray Competing Risks Model.

Mashiri C, Batidzirai J, Chifurira R, Chinhamu K Trop Med Infect Dis. 2024; 9(7).

PMID: 39058196 PMC: 11281671. DOI: 10.3390/tropicalmed9070154.

Numerous Asymptomatic Brain Tuberculomas Complicated by Fatal Tuberculous Meningitis.

Alavidze I, Shubitidze M, Khodeli G, Dvali S, Tskitishvili A Cureus. 2024; 16(6):e63090.

PMID: 39055453 PMC: 11270632. DOI: 10.7759/cureus.63090.

A retrospective study of tuberculosis prevalence and associated factors among HIV-positive key populations in Nigeria.

Ochonye B, Sanni O, Emmanuel G, Umoh P, Kalaiwo A, Abang R PLOS Glob Public Health. 2024; 4(7):e0003461.

PMID: 38995935 PMC: 11244832. DOI: 10.1371/journal.pgph.0003461.

HIV co-infection is associated with reduced Mycobacterium tuberculosis transmissibility in sub-Saharan Africa.

Windels E, Wampande E, Joloba M, Boom W, Goig G, Cox H PLoS Pathog. 2024; 20(5):e1011675.

PMID: 38696531 PMC: 11093396. DOI: 10.1371/journal.ppat.1011675.

References

Ayubi E, Doosti-Irani A, Moghaddam A, Sani M, Nazarzadeh M, Mostafavi E . The Clinical Usefulness of Tuberculin Skin Test versus Interferon-Gamma Release Assays for Diagnosis of Latent Tuberculosis in HIV Patients: A Meta-Analysis. PLoS One. 2016; 11(9):e0161983. PMC: 5021339. DOI: 10.1371/journal.pone.0161983. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Pretorius C, Glaziou P, Dodd P, White R, Houben R . Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality. AIDS. 2014; 28 Suppl 4:S477-87. PMC: 4247264. DOI: 10.1097/QAD.0000000000000484. View

Suthar A, Lawn S, Del Amo J, Getahun H, Dye C, Sculier D . Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9(7):e1001270. PMC: 3404110. DOI: 10.1371/journal.pmed.1001270. View

Wolday D, Hailu B, Girma M, Hailu E, Sanders E, Fontanet A . Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians. Int J Tuberc Lung Dis. 2003; 7(2):110-6. View

Grant A, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P . Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. AIDS. 2009; 23(18):2507-15. DOI: 10.1097/QAD.0b013e3283320dfd. View

Williams B, Granich R, De Cock K, Glaziou P, Sharma A, Dye C . Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A. 2010; 107(45):19485-9. PMC: 2984151. DOI: 10.1073/pnas.1005660107. View

Monge S, Diez M, Pulido F, Iribarren J, Campins A, Arazo P . Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. Int J Tuberc Lung Dis. 2014; 18(6):700-8. DOI: 10.5588/ijtld.13.0778. View

. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372(9635):293-9. PMC: 3130543. DOI: 10.1016/S0140-6736(08)61113-7. View

10.

Yirdaw K, Jerene D, Gashu Z, Edginton M, Kumar A, Letamo Y . Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014; 9(8):e104557. PMC: 4126726. DOI: 10.1371/journal.pone.0104557. View

11.

Sonnenberg P, Glynn J, Fielding K, Murray J, Godfrey-Faussett P, Shearer S . How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2004; 191(2):150-8. DOI: 10.1086/426827. View

12.

Andrews J, Noubary F, Walensky R, Cerda R, Losina E, Horsburgh C . Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012; 54(6):784-91. PMC: 3284215. DOI: 10.1093/cid/cir951. View

13.

Corbett E, Watt C, Walker N, Maher D, Williams B, Raviglione M . The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163(9):1009-21. DOI: 10.1001/archinte.163.9.1009. View

14.

Collins S, Jean Juste M, Koenig S, Secours R, Ocheretina O, Bernard D . CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001. Int J Tuberc Lung Dis. 2014; 19(1):50-7. DOI: 10.5588/ijtld.14.0217. View

15.

Antonucci G, Girardi E, Raviglione M, Ippolito G . Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA. 1995; 274(2):143-8. DOI: 10.1001/jama.274.2.143. View

16.

Williams B, Dye C . Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science. 2003; 301(5639):1535-7. DOI: 10.1126/science.1086845. View

17.

Golub J, Saraceni V, Cavalcante S, Pacheco A, Moulton L, King B . The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007; 21(11):1441-8. PMC: 3063947. DOI: 10.1097/QAD.0b013e328216f441. View

18.

Assebe L, Reda H, Wubeneh A, Lerebo W, Lambert S . The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health. 2015; 15:346. PMC: 4394593. DOI: 10.1186/s12889-015-1719-0. View

19.

Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, Shang N . 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9777):1588-98. DOI: 10.1016/S0140-6736(11)60204-3. View

20.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View